Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Up 286.3% in December

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 74,418 shares, a growth of 286.3% from the November 30th total of 19,264 shares. Based on an average trading volume of 172,559 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.1% of the shares of the stock are short sold. Currently, 0.1% of the shares of the stock are short sold. Based on an average trading volume of 172,559 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in shares of Xtant Medical during the second quarter worth about $26,000. Mink Brook Asset Management LLC raised its stake in Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after buying an additional 60,997 shares during the last quarter. Vanguard Group Inc. boosted its position in Xtant Medical by 4.6% during the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after acquiring an additional 104,159 shares during the last quarter. Crescent Grove Advisors LLC raised its position in shares of Xtant Medical by 94.3% in the 2nd quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock worth $304,000 after acquiring an additional 200,000 shares in the last quarter. Finally, AWM Investment Company Inc. bought a new stake in shares of Xtant Medical during the 2nd quarter valued at about $4,875,000. 69.33% of the stock is owned by institutional investors.

Xtant Medical Price Performance

Shares of XTNT stock traded down $0.00 on Thursday, hitting $0.78. 71,926 shares of the company’s stock were exchanged, compared to its average volume of 240,869. The stock has a market cap of $108.92 million, a P/E ratio of 77.88 and a beta of -0.05. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.21 and a quick ratio of 1.06. The company has a 50 day moving average of $0.73 and a 200 day moving average of $0.67. Xtant Medical has a 12 month low of $0.34 and a 12 month high of $0.95.

Xtant Medical (NYSEAMERICAN:XTNT) last released its quarterly earnings data on Monday, November 10th. The medical device company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.02. The company had revenue of $27.77 million for the quarter, compared to the consensus estimate of $32.70 million. Xtant Medical had a return on equity of 3.77% and a net margin of 1.32%.

Analyst Upgrades and Downgrades

Separately, BTIG Research cut their target price on Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a research report on Tuesday, November 11th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $1.50.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.